BIBW 1199.14 NSCLC Second Line
Laufzeit: 01.01.2011 - 31.12.2013
imported
Kurzfassung
A randomized, double-blind trial of oral BIBF1120 plus standard pemetrexed therapy versus placebo plus standard pemetrexed therapy stage IIIB/IV or recurrent NSCLC in second line
